panel-4-post-grant-proceedings-in-life-sciences

29 May 2026VideosAmericasPhil Hirschhorn, Panitch Law | Erin Dunston, Panitch Schwarze | Mythili Markowski, Regeneron | Victoria Pedanou, Sanofi

WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

Phil Hirschhorn, Partner at Panitch Law, moderates a discussion with Erin Dunston, Partner at Panitch Schwarze; Mythili Markowski, Patent Attorney at Regeneron; and Victoria Pedanou, Patent Counsel at Sanofi.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Why is 2026 already a record year for M&A activity?

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

More on this story

Editor's picks

Editor's picks

More features